(SYK) Stryker - Ratings and Ratios

Stryker Corporation (NYSE:SYK) is a global leader in medical technology, specializing in innovative solutions for healthcare professionals. The company operates through two primary segments: MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers a diverse range of products, including surgical equipment, surgical navigation systems, endoscopic systems, patient handling devices, emergency medical equipment, and intensive care disposable products. It also provides clinical communication systems, AI-assisted virtual care platforms, minimally invasive stroke treatment products, cranial and maxillofacial devices, dural substitutes, sealants, and orthobiologic and biosurgery solutions, such as synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment focuses on implants for joint replacements, trauma, and extremities surgeries, as well as thoracolumbar systems for spinal injuries and degenerative therapies. Strykers products are distributed globally through a network of company-owned subsidiaries, branches, and third-party dealers, reaching over 75 countries. Founded in 1941 and headquartered in Portage, Michigan, Stryker is committed to advancing medical technology to improve patient outcomes.

From a technical perspective, Strykers stock (SYK) is currently trading at 346.50, below its SMA 20 (359.38) and SMA 50 (373.11), indicating bearish momentum in the short to medium term. The stocks average 20-day volume is 1,718,782, with an ATR of 12.01, suggesting moderate volatility. Key resistance levels are at 386.3 and 362.3, while support levels are at 345.3, 336.8, and 324.0.

Fundamentally, Stryker has a market capitalization of 138.54 billion USD, with a trailing P/E of 46.70 and a forward P/E of 26.74, indicating expectations of future earnings growth. The companys P/B ratio of 6.71 reflects a premium valuation relative to its book value, while its P/S ratio of 6.13 suggests a strong revenue multiple. Strykers return on equity (RoE) of 14.51% highlights efficient profitability.